Get the Stockscreener App
75.27
0.63%
-0.48
Pre-market:
77.21
1.94
+2.58%
Inhibrx Biosciences Inc stock is traded at $75.27, with a volume of 315.44K.
It is down -0.63% in the last 24 hours and up +5.08% over the past month.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
See More
Previous Close:
$75.75
Open:
$75.75
24h Volume:
315.44K
Relative Volume:
1.58
Market Cap:
$1.10B
Revenue:
$1.30M
Net Income/Loss:
$-140.06M
P/E Ratio:
-8.3226
EPS:
-9.0441
Net Cash Flow:
$-129.83M
1W Performance:
+18.48%
1M Performance:
+5.08%
6M Performance:
+131.85%
1Y Performance:
+564.93%
1-Day Range:
$72.27
$77.06
1-Week Range:
$60.33
$77.35
52-Week Range:
$10.80
$94.56
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Name
Inhibrx Biosciences Inc
Sector
Industry
Phone
(858) 795-4220
Address
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
75.27 | 1.10B | 1.30M | -140.06M | -129.83M | -9.0441 |
VRTX
Vertex Pharmaceuticals Inc
|
436.27 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.87 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
799.65 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
322.11 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.66 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Initiated | Stifel | Buy |
| Jul-23-24 | Initiated | JMP Securities | Mkt Perform |
| Jan-23-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Mar-16-22 | Initiated | SMBC Nikko | Outperform |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Evercore ISI | Outperform |
View All
Inhibrx Biosciences Inc Stock (INBX) Latest News
Top Cybin (HELP) Competitors 2026 - MarketBeat
Does Stifel’s Focus on Ozekibart Milestones Reframe Inhibrx Biosciences' (INBX) Core Oncology Narrative? - simplywall.st
A Look At Inhibrx Biosciences (INBX) Valuation After Stifel Nicolaus Initiates Buy Coverage - Sahm
Weekly Recap: Is Inhibrx Biosciences Inc affected by consumer sentimentWeekly Earnings Recap & Real-Time Buy Signal Notifications - baoquankhu1.vn
This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Sahm
Stifel initiates coverage of Inhibrx Biosciences (INBX) with buy recommendation - MSN
Inhibrx stock gains as Stifel issues new Buy (INBX:NASDAQ) - Seeking Alpha
Inhibrx Biosciences advances efforts targeting rare sarcoma cancers - Traders Union
INBX Should I Buy - Intellectia AI
Discipline and Rules-Based Execution in INBX Response - Stock Traders Daily
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Down 5.7%What's Next? - MarketBeat
US Market Recap: Will Inhibrx Biosciences Inc stock recover after earnings2026 Risk Factors & Verified Momentum Watchlists - baoquankhu1.vn
Fundamentals Check: Will Inhibrx Biosciences Inc stock go up in YEAR2026 Opening Moves & Daily Volume Surge Signals - baoquankhu1.vn
Value Recap: Does Inhibrx Biosciences Inc have consistent dividend growthInsider Selling & Weekly Setup with ROI Potential - baoquankhu1.vn
Inhibrx Biosciences Inc. (INBX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Inhibrx Biosciences partners with Sarcoma Alliance to advance patient education resources - Traders Union
Retail Trends: Is Inhibrx Biosciences Inc stock undervalued right now2026 Earnings Impact & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Volume Recap: Is Inhibrx Biosciences Inc affected by consumer sentimentTrend Reversal & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Inhibrx Biosciences FY25 Review: Catalyst-Driven Hold Ahead Of Key 2026 Data (INBX) - Seeking Alpha
Ideas Watch: Is Inhibrx Biosciences Inc stock undervalued right nowEarnings Performance Report & Accurate Technical Buy Alerts - baoquankhu1.vn
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Down 6.6%Here's Why - marketbeat.com
Inhibrx Biosciences (INBX) Expected to Announce Earnings on Tuesday - MarketBeat
Behavioral Patterns of INBX and Institutional Flows - Stock Traders Daily
Inhibrx Biosciences Reports 2025 Financial Results - Intellectia AI
Inhibrx Reports Q4 Revenue of $0, Cash Balance at $124.2M - Intellectia AI
Inhibrx Biosciences Reports Q4 Earnings Miss - Intellectia AI
INBX SEC FilingsInhibrx Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Inhibrx Inc stock surges on Q4 2025 earnings and key 2026 pipeline milestones - ad-hoc-news.de
Inhibrx Biosciences, Inc. 2025 Annual Report – Clinical Pipeline, Regulatory Progress, and Company Overview - Minichart
Inhibrx Biosciences (NASDAQ:INBX) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Inhibrx Biosciences Q4 net loss narrows as expenses fall - TradingView
Inhibrx Biosciences 10-K: $1.3M revenue, EPS $(9.04) - TradingView
[10-K] Inhibrx Biosciences, Inc. Files Annual Report | INBX SEC FilingForm 10-K - Stock Titan
Inhibrx Biosciences (NASDAQ: INBX) details 2025 loss and 2026 trial plans - Stock Titan
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results - Nasdaq
Cancer drug filing tops Inhibrx milestones as cash reaches $124.2M - Stock Titan
Stock Analysis: Is Inhibrx Biosciences Inc a turnaround story2026 Key Lessons & High Accuracy Trade Alerts - baoquankhu1.vn
Boothbay Fund Management LLC Boosts Holdings in Inhibrx Biosciences, Inc. $INBX - marketbeat.com
Growth Value: What is Inhibrx Biosciences Incs P E ratio telling usQuarterly Trade Report & Technical Entry and Exit Alerts - baoquankhu1.vn
Latest INBX NewsInhibrx Announces Participation in Upcoming... - Stock Titan
Slotnik Capital LLC Sells 142,770 Shares of Inhibrx Biosciences, Inc. $INBX - MarketBeat
Inhibrx Biosciences Inc expected to post a loss of $2.08 a shareEarnings Preview - TradingView
7,388 Shares in Inhibrx Biosciences, Inc. $INBX Acquired by Dynamic Technology Lab Private Ltd - Defense World
(INBX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Inhibrx Biosciences : ESMO Sarcoma and Rare Cancers Congress 2026 (INBRX-109 in Ewing sarcoma Data Update Oral Presentation) - marketscreener.com
Market Trends: Is Inhibrx Biosciences Inc stock undervalued right now2026 Action & Growth Oriented Trade Recommendations - baoquankhu1.vn
Inhibrx Biosciences (INBX) to Release Quarterly Earnings on Monday - MarketBeat
Will Inhibrx Biosciences Inc stock recover after earnings2025 Key Lessons & Technical Pattern Based Buy Signals - baoquankhu1.vn
Inhibrx Announces Participation in Upcoming Scientific Conference - PR Newswire
How (INBX) Movements Inform Risk Allocation Models - Stock Traders Daily
INBX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Inhibrx Biosciences Inc Stock (INBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
3.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):